 |
|
Anticlotting drug found to be safe in sickle cell patients
October 12, 2007CHAPEL HILL - An intravenous "blood thinner" widely used in patients with acute coronary syndromes and during coronary artery stent placement appears to be safe in patients with sickle cell disease and may have beneficial anti-inflammatory effects, a small study at the University of North Carolina at Chapel Hill School of Medicine has found.
"We have tested a potentially promising drug in sickle cell patients, and the drug appears to be well tolerated. This gives us the impetus to go ahead with further studies of eptifibatide in these patients," said Dr. Leslie V. Parise, department chair and professor of biochemistry and biophysics at the UNC-Chapel Hill School of Medicine.
The hallmark of sickle cell disease is malformed red blood cells that can cause sudden painful episodes when they block small blood vessels. However, sickle cell patients are also at increased risk of developing multiple other complications, including strokes, lung complications and pulmonary hypertension.
The most frequent manifestations of sickle cell disorders are anemia and pain episodes. The episodic exacerbation of pain, often called "crises," is unpredictable and may occur often in some patients.
The only drug presently approved for the treatment of sickle cell disease is hydroxyurea, which has been shown to reduce the frequency of painful episodes.
Parise emphasized the need for further study. "We did not test this drug in patients who are in crisis, and we cannot recommend that doctors prescribe this drug for sickle cell patients at this time," she said.
The results of the study were published online (Oct. 6) in the British Journal of Haematology.
The researchers gave intravenous infusions of eptifibatide (brand name Integrilin) to four patients with sickle cell anemia who were not experiencing pain episodes. "They did well clinically. They did not experience any deleterious changes in their blood tests or have a pain episode," said coauthor Dr. Kenneth I. Ataga, assistant professor of medicine at UNC-Chapel Hill.
In the current study, blood tests showed that while the patients' liver, kidney and other functions remained at baseline, several indicators of inflammation decreased, including levels of a protein called CD40L known to play a role in inflammation and in blood clotting.
Previous studies conducted by Sheritha Lee a graduate student in Parise's lab showed that patients with sickle cell disease have CD40L levels that are as much as 30 times higher than in patients without the disease. Eptifibatide's known ability to decrease CD40L led the researchers to study whether the drug might help sickle cell patients.
University of North Carolina at Chapel Hill
The most frequent manifestations of sickle cell disorders are anemia and pain episodes. The episodic exacerbation of pain, often called "crises," is unpredictable and may occur often in some patients.
The only drug presently approved for the treatment of sickle cell disease is hydroxyurea, which has been shown to reduce the frequency of painful episodes.
Parise emphasized the need for further study. "We did not test this drug in patients who are in crisis, and we cannot recommend that doctors prescribe this drug for sickle cell patients at this time," she said.
The results of the study were published online (Oct. 6) in the British Journal of Haematology.
The researchers gave intravenous infusions of eptifibatide (brand name Integrilin) to four patients with sickle cell anemia who were not experiencing pain episodes. "They did well clinically. They did not experience any deleterious changes in their blood tests or have a pain episode," said coauthor Dr. Kenneth I. Ataga, assistant professor of medicine at UNC-Chapel Hill.
In the current study, blood tests showed that while the patients' liver, kidney and other functions remained at baseline, several indicators of inflammation decreased, including levels of a protein called CD40L known to play a role in inflammation and in blood clotting.
Previous studies conducted by Sheritha Lee a graduate student in Parise's lab showed that patients with sickle cell disease have CD40L levels that are as much as 30 times higher than in patients without the disease. Eptifibatide's known ability to decrease CD40L led the researchers to study whether the drug might help sickle cell patients.
University of North Carolina at Chapel Hill
Sickle Cell Current Events and Sickle Cell News RSSChildren's national co-leads nationwide study of landmark sickle cell treatment
Children's National Medical Center immunologist and blood and marrow transplant physician Naynesh Kamani, MD, will serve as the study co-chair for a new national clinical trial of unrelated donor marrow and umbilical cord blood transplants for severe sickle cell disease.
Most generalists reluctant to provide primary care for young adults with chronic illness
The majority of general internists and pediatricians in the United States are not comfortable serving as primary care providers for young adults with complex chronic illnesses that originate during childhood, according to findings from a new national survey.
Consortium develops new method to manipulate genetic material
A multi-institutional team of researchers, including scientists at the University of Minnesota Medical School, have developed a powerful tool for genomic research and medicine.
Gaining ground on sickle cell disease
Although sickle cell disease is a single-gene disorder, its symptoms are highly variable. In a study published online July 14 by the Proceedings of the National Academy of Sciences, scientists at Children's Hospital Boston and the Dana Farber Cancer Institute (DFCI), in collaboration with the Broad Institute of MIT and Harvard, report five gene variants that could potentially be helpful in predicting sickle cell disease severity, perhaps even leading to better treatment approaches in the future.
Effective treatment for sickle cell underused by doctors
Uncertainties about proper use and possible long-term effects of hydroxyurea in the treatment of sickle cell anemia may be wrongly influencing doctors to avoid prescribing it to those in serious need, according to results of a literature review by specialists at Johns Hopkins.
Statistical tool could explain gene study variations
While scientists are using the human genome to associate certain genes with disease, Dr. Hongyan Xu wants to ensure they are accounting for natural variations in those genes.
Major 'missed' biochemical pathway emerges as important in virtually all cells
A new study by Duke University researchers provides more evidence that the nitric oxide (NO) system in the life of a cell plays a key role in disease, and the findings point to ways to improve treatment of illnesses such as heart disease and cancer.
For children with sickle cell disease, lung disease is part of the package
Children with sickle cell disease (SCD) have a significantly sharper decline in lung function with age when compared to other children of the same race and age.
Clumps of red and white blood cells may contribute to sickle cell disease
It's long been known that patients with sickle cell disease have malformed, "sickle-shaped" red blood cells - which are normally disc-shaped - that can cause sudden painful episodes when they block small blood vessels.
Researchers at UCLA engineering discover theoretical model to predict jamming
Researchers at the UCLA Henry Samueli School of Engineering and Applied Science have come up with a theoretical model to predict when granular materials become jammed.
More Sickle Cell Current Events and Sickle Cell News Articles
 | Understanding Sickle Cell Disease (Understanding Health and Sickness Series) by Ph.D., Miriam Bloom |
 | In the Blood: Sickle Cell Anemia and the Politics of Race (Critical Histories) by Melbourne Tapper Although it strikes individuals from a variety of backgrounds, sickle cell anemia has always been known as a "black" disease in America. In the Blood argues that ever since the discovery in 1910 and subsequent scientific analysis of the disease, sickle cell anemia has been manipulated to serve social ends-as a tool for securing white identity and a way to establish a hierarchy based on European... |
| Sickle Cell Disease (Oxford Medical Publications) by Graham R. Serjeant Sickle cell disease was one of the first diseases to be explained at the molecular level. In the years since the first edition of this book was published, further advances have been made, and much has been learned about the causes of variation in the natural history of the disease and in the patterns of morbidity and mortality. The role of genetic modifiers such as alpha-thalassemia and... | |
 | Hope and Destiny: A Patient's and Parent's Guide to Sickle Cell Disease and Sickle Cell Trait by Allan F., Jr. Platt, Alan, M.D. Sacerdote An up-to-date, informative, and personal discussion of sickle-cell anemia, this guide provides information on medically proven methods of treatment along with patient vignettes. Written primarily for African Americans, who comprise the majority of the victims of sickle-cell anemia, this handbook for patients and those who live or work with them examines the complex issues that surround this... |
 | Our Little Blessing: A Story About Sickle Cell Disease by r.m. reid Our Little Blessing: A Story About Sickle Cell Disease relates how this potentially devastating medical condition affects the individuals who live with SCD every day. Survivors such as Gigi, the little girl whose story is told here, face daily challenges that demand careful medical care and attention. This unique work shares how one family has learned to cope with SCD and reflects the courage... |
 | Sickle Cell Disease (Diseases and Disorders) by Lizabeth Peak |
 | Dying in the City of the Blues: Sickle Cell Anemia and the Politics of Race and Health by Keith Wailoo This history of the recognition, research, and treatment of sickle cell anemia provides important insight into the African American experience, race relations, and the politics of science, medicine, and... |
 | The Sickle Cell Anemia Update (Disease Update) by Alvin Silverstein, Virginia B. Silverstein, Laura Silverstein Nunn |
 | Menace In My Blood: My Affliction With Sickle-Cell Anemia by Ola Tamedu Sickle-cell disease is a unique inherited and incurable condition of the blood cells which, according to doctors, has similarities with virtually all disease conditions known to mankind, including AIDS and cancer. Commonly affecting Africans and those with an African ancestry, the disease is also prevalent among Arabs, Turks, Greeks, Italians (chiefly Sicilians), Iranians and Indians. As a... |
 | Sickle Cell Disease: Pathophysiology, Diagnosis, and Management Sickle cell disease is a complex disease with a genetic mutation producing a wide variety of manifestations. It is of great public health importance nationally and internationally. While the conclusions of this study support the generally accepted views on the disease, the book provides the most recent information and state-of-the-art knowledge on the subject. The book is unique in that it... |
| © 2008 BrightSurf.com |